Loading data for MBX — first visit, this takes a few seconds.
MBX Biosciences, Inc. (MBX)
NasdaqGS: MBX
· Real-Time Price · USD
63.00
-3.39 (-5.11%)
At close: Sep 01, 2026, 3:59 PM
60.93
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
MBX Biosciences, Inc. (MBX) Stock Price, Analysis & Data
-5.11% (1D)
| Bid | 46.36 |
| Market Cap | 2.93B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -104M |
| 0.00 | |
| -2.37 | |
| n/a | |
| -15.41 | |
| P/B (ttm) | 7.13 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 5, 2026 |
| Ask | 81.42 |
| Volume | 307,645 |
| Avg. Volume (20D) | 760,841 |
| Open | 66.14 |
| Previous Close | 66.39 |
| Day's Range | 62.99 - 66.14 |
| 52-Week Range | 9.63 - 72.64 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2024
Employees 63
Stock Exchange NasdaqGS
Ticker Symbol MBX
Website https://mbxbio.com
Financial Performance
In 2025, MBX Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -86.97M, an increase of 40.45%.
Financial StatementsEarnings Surprise
MBX Biosciences has released their quarterly earnings on Aug 6, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.78 misses estimates by -0.19, with -34.48% YoY decline.
MBX Biosciences, Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2